Skip to main content

Health economic modeling for medical technologies in Europe

Early and comprehensive economic models to determine economic value proposition and inform healthcare decision-makers

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Development of models for assessment of technologies for coverage within basic health insurance in the Netherlands

The Dutch Healthcare Institute (ZIN) advises the Ministry of Health, Welfare and Sport (VWS) on the reimbursement of medicines and medical procedures under the Basic Health Insurance Package. 

A disease model is a mathematical description of a disease and the treatments for this disease. Disease models can be used to estimate the long-term consequences of treatment. The model also makes the costs of treatment clear.

In October 2022, the ZIN launched the project “Continued development of coverage management: Implementation of the use of disease models”. This project will run for three years to gain more knowledge about the development and application of disease models. Disease models have already been developed for melanoma (skin cancer), multiple myeloma and diabetes. The project is developing two new disease models and working on methods to make insights from these types of models for package management. 

The publication of the first package advice based on a disease model is planned for 2024.

The full details in Dutch can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.